A new antiinflammatory agent (EGIS-5645) without gastrointestinal side-effect.
The compound EGIS-5645 is a potent antipyretic agent possessing analgesic and antiinflammatory properties. The drug is active in antiinflammatory models such as carrageenin oedema and adjuvant arthritis. EGIS-5645 shows practically no gastro-ulcerogenic effect. The molecule does not inhibit either prostaglandin biosynthesis or soybean lipoxygenase enzyme activity.
Gigler
G
G
EGIS Pharmaceuticals, Budapest, Hungary.
Kiszelly
E
E
Tömpe
P
P
Kovács
G
G
Gadó
K
K
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000633:toxicity*; D001923:Brain Chemistry / Q000187:drug effects; D002351:Carrageenan; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D066298:In Vitro Techniques; D016859:Lipoxygenase Inhibitors; D008297:Male; D011453:Prostaglandins / Q000096:biosynthesis; D011743:Pyrimidines / Q000494:pharmacology / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D013276:Stomach Ulcer / Q000139:chemically induced / Q000503:physiopathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016859:Lipoxygenase Inhibitors; D011453:Prostaglandins; D011743:Pyrimidines; C033222:diaveridine; D002351:Carrageenan